Aptis Signs MOU with Wuxi XDC for Next-Generation ADC Development
Aptis has signed a business agreement with XuXi XDC for the development of next-generation ADC. Photo by Aptis
View original imageAppTis, a company specializing in the development of antibody-drug conjugates (ADC), announced on the 12th that it has signed a memorandum of understanding (MOU) with WuXi XDC, a global ADC CRDMO specialist, to develop next-generation ADC therapeutics.
This MOU aims to accelerate the development speed and improve the efficiency of next-generation ADCs by combining AppTis's linker platform technology, 'AbClick®,' with WuXi XDC's CMC development platform.
WuXi XDC will adopt AppTis's AbClick platform and selective drug conjugate technology. Additionally, WuXi XDC will leverage its global network to provide opportunities for AppTis's technology to expand globally.
Both companies plan to strengthen their CMC platform capabilities to showcase innovation and cutting-edge solutions in the ADC field, including accelerating the selection of preclinical candidate substances for global clients, speeding up next-generation ADC development, and shortening CMC development schedules.
Jimmy Lee, CEO of WuXi XDC, stated, "This collaboration with AppTis is about advancing innovation through a strategic partnership and creating meaningful value for customers. We expect that the combination of our technologies will enable us to provide customized ADC development solutions tailored to our clients."
Han Tae-dong, CEO of AppTis, explained, "The synergy between AppTis's antibody-drug conjugate technology and WuXi XDC's extensive global network and ADC manufacturing capabilities will be significant. We will lead and support the development of groundbreaking ADC therapeutics, providing opportunities that benefit patients worldwide."
Hot Picks Today
At President Lee's Call to "Give Enough to Shock," Whistleblower Rewards Become a Real Lottery
- If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Meanwhile, AppTis is a specialized ADC development company that possesses the third-generation linker technology 'AbClick,' which enables selective binding to desired sites.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
